泛冠状病毒融合抑制剂用于应对 COVID-19 和其他新发冠状病毒传染病。
Pan-coronavirus fusion inhibitors to combat COVID-19 and other emerging coronavirus infectious diseases.
机构信息
Key Laboratory of Medical Molecular Virology (MOE/NHC/CAMS), School of Basic Medical Sciences, Shanghai Frontiers Science Center of Pathogenic Microbes and Infection, Shanghai Institute of Infectious Disease and Biosecurity, Fudan University, Shanghai, China.
出版信息
J Med Virol. 2023 Jan;95(1):e28143. doi: 10.1002/jmv.28143. Epub 2022 Sep 22.
Abstract
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the causative agent of the currently ongoing coronavirus disease 2019 (COVID-19) pandemic, has posed a serious threat to global public health. Recently, several SARS-CoV-2 variants of concern (VOCs) have emerged and caused numerous cases of reinfection in convalescent COVID-19 patients, as well as breakthrough infections in vaccinated individuals. This calls for the development of broad-spectrum antiviral drugs to combat SARS-CoV-2 and its VOCs. Pan-coronavirus fusion inhibitors, targeting the conserved heptad repeat 1 (HR1) in spike protein S2 subunit, can broadly and potently inhibit infection of SARS-CoV-2 and its variants, as well as other human coronaviruses. In this review, we summarized the most recent development of pan-coronavirus fusion inhibitors, such as EK1, EK1C4, and EKL1C, and highlighted their potential application in combating current COVID-19 infection and reinfection, as well as future emerging coronavirus infectious diseases.
摘要
严重急性呼吸综合征冠状病毒 2（SARS-CoV-2）是导致目前正在流行的 2019 年冠状病毒病（COVID-19）大流行的病原体，对全球公共卫生构成了严重威胁。最近，一些引起关注的 SARS-CoV-2 变体（VOC）已经出现，并导致大量 COVID-19 康复患者再次感染，以及接种疫苗的个体突破性感染。这就需要开发广谱抗病毒药物来对抗 SARS-CoV-2 及其 VOC。针对刺突蛋白 S2 亚单位保守的七肽重复 1（HR1）的泛冠状病毒融合抑制剂，可以广泛而有效地抑制 SARS-CoV-2 及其变体以及其他人类冠状病毒的感染。在这篇综述中，我们总结了泛冠状病毒融合抑制剂的最新进展，例如 EK1、EK1C4 和 EKL1C，并强调了它们在对抗当前 COVID-19 感染和再感染以及未来新发冠状病毒传染病中的潜在应用。
相似文献
1
Pan-coronavirus fusion inhibitors to combat COVID-19 and other emerging coronavirus infectious diseases.泛冠状病毒融合抑制剂用于应对 COVID-19 和其他新发冠状病毒传染病。
J Med Virol. 2023 Jan;95(1):e28143. doi: 10.1002/jmv.28143. Epub 2022 Sep 22.
2
Inhibition of SARS-CoV-2 (previously 2019-nCoV) infection by a highly potent pan-coronavirus fusion inhibitor targeting its spike protein that harbors a high capacity to mediate membrane fusion.强效泛冠状病毒融合抑制剂抑制 SARS-CoV-2（前称 2019-nCoV）感染，该抑制剂针对病毒的刺突蛋白，具有很强的介导膜融合能力。
Cell Res. 2020 Apr;30(4):343-355. doi: 10.1038/s41422-020-0305-x. Epub 2020 Mar 30.
3
Design of Potent Membrane Fusion Inhibitors against SARS-CoV-2, an Emerging Coronavirus with High Fusogenic Activity.针对高融合活性新兴冠状病毒 SARS-CoV-2 的有效膜融合抑制剂设计。
J Virol. 2020 Jul 1;94(14). doi: 10.1128/JVI.00635-20.
4
A dePEGylated Lipopeptide-Based Pan-Coronavirus Fusion Inhibitor Exhibits Potent and Broad-Spectrum Anti-HIV-1 Activity without Eliciting Anti-PEG Antibodies.一种去聚乙二醇化的脂肽类泛冠状病毒融合抑制剂具有强大且广谱的抗 HIV-1 活性，且不会诱导抗聚乙二醇抗体产生。
Int J Mol Sci. 2023 Jun 5;24(11):9779. doi: 10.3390/ijms24119779.
5
SARS-CoV-2 Omicron XBB subvariants exhibit enhanced fusogenicity and substantial immune evasion in elderly population, but high sensitivity to pan-coronavirus fusion inhibitors.严重急性呼吸综合征冠状病毒2型奥密克戎XBB亚变体在老年人群中表现出增强的融合性和显著的免疫逃逸能力，但对泛冠状病毒融合抑制剂高度敏感。
J Med Virol. 2023 Mar;95(3):e28641. doi: 10.1002/jmv.28641.
6
A Modified Fibronectin Type III Domain-Conjugated, Long-Acting Pan-Coronavirus Fusion Inhibitor with Extended Half-Life.一种改良的纤维连接蛋白 III 结构域缀合的长效泛冠状病毒融合抑制剂，半衰期延长。
Viruses. 2022 Mar 22;14(4):655. doi: 10.3390/v14040655.
7
Repurposing fusion inhibitor peptide against SARS-CoV-2.重新利用融合抑制剂肽来对抗 SARS-CoV-2。
J Comput Chem. 2021 Dec 15;42(32):2283-2293. doi: 10.1002/jcc.26758. Epub 2021 Sep 30.
8
A highly potent and stable pan-coronavirus fusion inhibitor as a candidate prophylactic and therapeutic for COVID-19 and other coronavirus diseases.一种高效且稳定的泛冠状病毒融合抑制剂，作为COVID-19和其他冠状病毒疾病的预防性和治疗性候选药物。
Acta Pharm Sin B. 2022 Apr;12(4):1652-1661. doi: 10.1016/j.apsb.2021.07.026. Epub 2021 Aug 2.
9
Design of a bifunctional pan-sarbecovirus entry inhibitor targeting the cell receptor and viral fusion protein.设计一种针对细胞受体和病毒融合蛋白的双功能泛沙贝科病毒进入抑制剂。
J Virol. 2023 Aug 31;97(8):e0019223. doi: 10.1128/jvi.00192-23. Epub 2023 Aug 14.
10
Structural and functional basis for pan-CoV fusion inhibitors against SARS-CoV-2 and its variants with preclinical evaluation.针对 SARS-CoV-2 及其变体的泛冠状病毒融合抑制剂的结构和功能基础及其临床前评估。
Signal Transduct Target Ther. 2021 Jul 29;6(1):288. doi: 10.1038/s41392-021-00712-2.
引用本文的文献
1
Development of COVID-19 Vaccine Candidates Using Attenuated Recombinant Vesicular Stomatitis Virus Vectors with M Protein Mutations.利用具有M蛋白突变的减毒重组水疱性口炎病毒载体开发COVID-19候选疫苗
Viruses. 2025 Jul 30;17(8):1062. doi: 10.3390/v17081062.
2
MERS-related coronavirus circulating in pangolins exhibits strong fusogenicity in human cells and high sensitivity to fusion inhibitors.穿山甲中传播的中东呼吸综合征相关冠状病毒在人类细胞中表现出很强的融合性，并对融合抑制剂高度敏感。
Cell Rep Med. 2025 Aug 19;6(8):102277. doi: 10.1016/j.xcrm.2025.102277. Epub 2025 Aug 6.
3
Fear of COVID-19 Diagnosis and Cannabis Use Patterns Among Adults with Chronic Health Conditions: Results from COVID-19 Cannabis Health Study.患有慢性健康状况的成年人对新冠病毒诊断的恐惧及大麻使用模式：新冠病毒大麻健康研究结果
J Psychoactive Drugs. 2024 Oct 28:1-10. doi: 10.1080/02791072.2024.2421903.
4
The Design, Synthesis and Mechanism of Action of Paxlovid, a Protease Inhibitor Drug Combination for the Treatment of COVID-19.用于治疗新冠病毒病的蛋白酶抑制剂药物组合帕罗韦德的设计、合成及作用机制
Pharmaceutics. 2024 Feb 2;16(2):217. doi: 10.3390/pharmaceutics16020217.
5
Clinical development of antivirals against SARS-CoV-2 and its variants.抗SARS-CoV-2及其变体抗病毒药物的临床开发。
Curr Res Microb Sci. 2023 Dec 2;6:100208. doi: 10.1016/j.crmicr.2023.100208. eCollection 2024.
6
Strategies for the development and approval of COVID-19 vaccines and therapeutics in the post-pandemic period.后疫情时期 COVID-19 疫苗和疗法的研发与审批策略。
Signal Transduct Target Ther. 2023 Dec 21;8(1):466. doi: 10.1038/s41392-023-01724-w.
7
Structure and Function of the SARS-CoV-2 6-HB Fusion Core and Peptide-Based Fusion Inhibitors: A Review.严重急性呼吸综合征冠状病毒2 6-螺旋束融合核心与基于肽的融合抑制剂的结构与功能综述
Curr Med Chem. 2023 Nov 24. doi: 10.2174/0109298673265694231113061842.
8
Low-sugar universal mRNA vaccine against coronavirus variants with deletion of glycosites in the S2 or stem of SARS-CoV-2 spike messenger RNA (mRNA).针对冠状病毒变体的低糖通用 mRNA 疫苗，该疫苗在 SARS-CoV-2 刺突信使 RNA（mRNA）的 S2 或茎中删除了糖基化位点。
Proc Natl Acad Sci U S A. 2023 Dec 5;120(49):e2314392120. doi: 10.1073/pnas.2314392120. Epub 2023 Nov 27.
9
Mathematical Modeling of Virus-Mediated Syncytia Formation: Past Successes and Future Directions.病毒介导的合胞体形成的数学建模：过去的成功与未来的方向。
Results Probl Cell Differ. 2024;71:345-370. doi: 10.1007/978-3-031-37936-9_17.
10
Phenothiazines Inhibit SARS-CoV-2 Entry through Targeting Spike Protein.吩噻嗪类通过靶向刺突蛋白抑制 SARS-CoV-2 进入。
Viruses. 2023 Jul 31;15(8):1666. doi: 10.3390/v15081666.
本文引用的文献
1
Targeting an evolutionarily conserved "E-L-L" motif in spike protein to identify a small molecule fusion inhibitor against SARS-CoV-2.靶向刺突蛋白中一个进化保守的“E-L-L”基序以鉴定一种抗SARS-CoV-2的小分子融合抑制剂。
PNAS Nexus. 2022 Oct 22;1(5):pgac198. doi: 10.1093/pnasnexus/pgac198. eCollection 2022 Nov.
2
A novel cyclic γ-AApeptide-based long-acting pan-coronavirus fusion inhibitor with potential oral bioavailability by targeting two sites in spike protein.一种新型的基于环状γ-氨基酸肽的长效泛冠状病毒融合抑制剂，通过靶向刺突蛋白中的两个位点具有潜在的口服生物利用度。
Cell Discov. 2022 Sep 8;8(1):88. doi: 10.1038/s41421-022-00455-6.
3
Neutralization of distinct Omicron sublineages by longitudinal vaccination sera.纵向接种疫苗血清对不同奥密克戎亚谱系的中和作用。
J Med Virol. 2022 Nov;94(11):5090-5092. doi: 10.1002/jmv.28017. Epub 2022 Jul 30.
4
Sensitivity to Vaccines, Therapeutic Antibodies, and Viral Entry Inhibitors and Advances To Counter the SARS-CoV-2 Omicron Variant.疫苗、治疗性抗体和病毒进入抑制剂的敏感性以及应对 SARS-CoV-2 奥密克戎变异株的进展。
Clin Microbiol Rev. 2022 Sep 21;35(3):e0001422. doi: 10.1128/cmr.00014-22. Epub 2022 Jun 6.
5
Origin, virological features, immune evasion and intervention of SARS-CoV-2 Omicron sublineages.奥密克戎亚系的起源、病毒学特征、免疫逃逸与干预。
Signal Transduct Target Ther. 2022 Jul 19;7(1):241. doi: 10.1038/s41392-022-01105-9.
6
Neutralization mechanism of a human antibody with pan-coronavirus reactivity including SARS-CoV-2.针对包括 SARS-CoV-2 在内的多种冠状病毒具有反应性的人源中和抗体的中和机制。
Nat Microbiol. 2022 Jul;7(7):1063-1074. doi: 10.1038/s41564-022-01155-3. Epub 2022 Jun 30.
7
Potency of Fusion-Inhibitory Lipopeptides against SARS-CoV-2 Variants of Concern.融合抑制脂肽对关注的 SARS-CoV-2 变异株的效力。
mBio. 2022 Jun 28;13(3):e0124922. doi: 10.1128/mbio.01249-22. Epub 2022 Jun 13.
8
A Modified Fibronectin Type III Domain-Conjugated, Long-Acting Pan-Coronavirus Fusion Inhibitor with Extended Half-Life.一种改良的纤维连接蛋白 III 结构域缀合的长效泛冠状病毒融合抑制剂，半衰期延长。
Viruses. 2022 Mar 22;14(4):655. doi: 10.3390/v14040655.
9
Coronavirus Entry Inhibitors.冠状病毒进入抑制剂
Adv Exp Med Biol. 2022;1366:101-121. doi: 10.1007/978-981-16-8702-0_7.
10
Structural definition of a pan-sarbecovirus neutralizing epitope on the spike S2 subunit.刺突 S2 亚基上泛沙贝科病毒中和表位的结构定义。
Commun Biol. 2022 Apr 11;5(1):342. doi: 10.1038/s42003-022-03262-7.
Zotero 插件